Journal of the American Academy of Dermatology
Volume 60, Issue 5 , Pages 808-813 , May 2009

Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions

References 

  1. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc. 2006;81:500–507
  2. Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?. J Am Acad Dermatol. 1995;33:1000–1007
  3. Gimotty PA, Botbyl J, Soong SJ, Guerry D. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2005;23:8065–8075
  4. Quinn CM, Wright NA. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol. 1990;160:93–102
  5. Tachibana KE, Gonzalez MA, Coleman N. Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol. 2005;205:123–129
  6. Li LX, Crotty KA, McCarthy SW, Palmer AA, Kril JJ. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22:489–495
  7. Kanter L, Blegen H, Wejde J, Lagerlöf B, Larsson O. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties. Melanoma Res. 1995;5:345–350
  8. Korabiowska M, Brinck U, Middel P, Brinkmann U, Berger H, Radzun HJ, et al. Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance. Anticancer Res. 2000;20:1781–1785
  9. Lebe B, Pabuççuoğlu U, Ozer E. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol. 2007;15:160–164
  10. Hazan C, Melzer K, Panageas KS, Li E, Kamino H, Kopf A, et al. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer. 2002;95:634–640
  11. Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol. 2001;44:188–192
  12. Kaleem Z, Lind AC, Humphrey PA, Sueper RH, Swanson PE, Ritter JH, et al. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?. Mod Pathol. 2000;13:217–222
  13. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117–122
  14. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433–444
  15. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999;5:2121–2132
  16. Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, Hur SY, et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res. 2004;10:8386–8395
  17. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol. 2004;57:1057–1062
  18. Schrader C, Janssen D, Klapper W, Siebmann JU, Meusers P, Brittinger G, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005;93:939–945
  19. Gambichler T, Bischoff S, Bechara FG, Altmeyer P, Kreuter A. Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders. J Dermatol Sci. 2008;49:125–132
  20. Liu H, Takeuchi S, Moroi Y, Lin N, Urabe K, Kokuba H, et al. Expression of minichromosome maintenance 5 protein in proliferative and malignant skin diseases. Int J Dermatol. 2007;46:1171–1176
  21. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, et al. Melanoma Group of the European Organization for Research and Treatment of Cancer. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472–482
  22. Boyd AS, Shakhtour B, Shyr Y. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases. J Am Acad Dermatol. 2008;58:750–754

 This work was funded by Forschungsförderung Ruhr-Universität Bochum Medizinischen Fakultät (FoRUM, Project No. F615-2008).

 Conflicts of interest: None declared.

PII: S0190-9622(09)00125-X

doi: 10.1016/j.jaad.2009.01.028

Journal of the American Academy of Dermatology
Volume 60, Issue 5 , Pages 808-813 , May 2009

Article Tools

* Image Usage & Resolution